Industry News
YERVOY™ (Ipilimumab) Approved For The Treatment Of Previously-Treated Advanced Melanoma In The EU
Jul 15, 2011
Bristol-Myers Squibb announced that the European Commission has approved YERVOY™ (ipilimumab) for the treatment of adult patients with previously-treated advanced melanoma... Read More
YERVOY™ (Ipilimumab) Approved For The Treatment Of Previously-Treated Advanced Melanoma In The EU
Jul 14, 2011
Bristol-Myers Squibb today announced that the European Commission has approved YERVOY™ (ipilimumab) for the treatment of adult patients with previously-treated advanced melanoma... Read More
23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated In Clinical Trials Using The ExAblate(R) Non-Invasive Prostate System
Jul 14, 2011
InSightec Ltd., the global leader in MR-guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate® system for treating uterine fibroids, announced today that 23 patients with organ confined low risk prostate cancer have already been treated with its ExAblate® system in clinical trials, showing promising initial results... Read More
Short-Term Hormone Therapy Plus Radiation Therapy Increases Survival For Men With Early-Stage Prostate Cancer
Jul 14, 2011
Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in the July 14 ... Read More
Lycopene May Help Prevent Prostate Cancer In African Americans
Jul 14, 2011
Lycopene, a red pigment that gives tomatoes and certain other fruits and vegetables their color, could help prevent prostate cancer, especially in African American men, according to new research at the University of Illinois at Chicago... Read More
PSA Test For Men Could Get A Second Life For Breast Cancer In Women
Jul 13, 2011
The widely known PSA blood test for prostate cancer in men may get a second life as a much-needed new test for breast cancer, the most common form of cancer in women worldwide, scientists are reporting in a new study in the ACS journal Analytical Chemistry... Read More
23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated In Trials Using The ExAblate® Non-Invasive Prostate Cancer System
Jul 13, 2011
the global leader in MR-guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate® system for treating uterine fibroids, announced today that 23 patients with organ confined low risk prostate cancer have already been treated with its ExAblate® system in clinical trials, showing promising initial results... Read More
Harnessing The Body's Own Chemistry To Treat Human Ovarian Cancer
Jul 13, 2011
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that a low dose of the opioid antagonist naltrexone (LDN) has an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture and xenografts established in nude mice. When LDN is combined with chemotherapy, there is an additive inhibitory action on tumorigenesis... Read More
CYTAVIS' Aviscumine Improves Survival Of Patients With Metastatic Melanoma In A Phase II Trial
Jul 13, 2011
CYTAVIS BioPharma GmbH, a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological and immunological diseases, today announced Phase II data demonstrating that its lead compound Aviscumine (CY503), an immune potentiator, may improve survival of patients with refractory metastatic melanoma (stage IV)... Read More
Isoray Announces World's First Cesium-131 Treatment For Lung Cancer Using Da Vinci Robotic Surgery System
Jul 12, 2011
IsoRay, Inc. (Amex: ISR) announced another milestone, today, in the use of its proprietary Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) in mesh. Dr... Read More
Previous Page Next Page